PTX and 5-aza-2′-deoxycytidine use lymphoid enhancer-binding factor 1 and the Wnt/β-catenin pathway to synergistically interact against RCC (68).At the molecular targeting level, neurokinin-1 receptor (NK1R) antagonists (e.g., aprepitant) and calcitonin gene-related peptide (CGRP) receptor antagonists (e.g., erenumab) have also demonstrated antitumor potential. The gene discussed is TACR1; the disease is renal cell carcinoma.